FI964634A0 - Flutikasonpropionatformulationer - Google Patents

Flutikasonpropionatformulationer

Info

Publication number
FI964634A0
FI964634A0 FI964634A FI964634A FI964634A0 FI 964634 A0 FI964634 A0 FI 964634A0 FI 964634 A FI964634 A FI 964634A FI 964634 A FI964634 A FI 964634A FI 964634 A0 FI964634 A0 FI 964634A0
Authority
FI
Finland
Prior art keywords
pct
formulation
sec
date
pub
Prior art date
Application number
FI964634A
Other languages
English (en)
Finnish (fi)
Other versions
FI964634A (sv
FI118512B (sv
Inventor
David Alexander Tainsh
Trevor Leslie Ilott
Dorothy Jill Snell
Li Fong Lam
Original Assignee
Glaxo Wellcome Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Australia Ltd filed Critical Glaxo Wellcome Australia Ltd
Publication of FI964634A0 publication Critical patent/FI964634A0/sv
Publication of FI964634A publication Critical patent/FI964634A/sv
Application granted granted Critical
Publication of FI118512B publication Critical patent/FI118512B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI964634A 1994-05-21 1996-11-20 Flutikasonpropionatformulationer FI118512B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
GB9410222 1994-05-21
PCT/EP1995/001913 WO1995031964A1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations
EP9501913 1995-05-19

Publications (3)

Publication Number Publication Date
FI964634A0 true FI964634A0 (sv) 1996-11-20
FI964634A FI964634A (sv) 1996-11-20
FI118512B FI118512B (sv) 2007-12-14

Family

ID=10755515

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964634A FI118512B (sv) 1994-05-21 1996-11-20 Flutikasonpropionatformulationer

Country Status (29)

Country Link
US (1) US5993781A (sv)
EP (1) EP0760649B1 (sv)
JP (1) JPH10500420A (sv)
KR (2) KR970703132A (sv)
CN (1) CN1098680C (sv)
AT (1) ATE207734T1 (sv)
AU (1) AU710821B2 (sv)
BR (1) BR9507746A (sv)
CA (1) CA2190763A1 (sv)
CY (1) CY2294B1 (sv)
CZ (1) CZ285966B6 (sv)
DE (1) DE69523587T2 (sv)
DK (1) DK0760649T3 (sv)
ES (1) ES2164767T3 (sv)
FI (1) FI118512B (sv)
GB (1) GB9410222D0 (sv)
HK (1) HK1004192A1 (sv)
HU (1) HU223316B1 (sv)
IL (1) IL113794A (sv)
MX (1) MX9605650A (sv)
NO (1) NO313785B1 (sv)
NZ (1) NZ287425A (sv)
PL (1) PL180318B1 (sv)
PT (1) PT760649E (sv)
RU (1) RU2161485C2 (sv)
SI (1) SI0760649T1 (sv)
TW (1) TW438604B (sv)
WO (1) WO1995031964A1 (sv)
ZA (1) ZA954101B (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
DE60332212D1 (de) 2002-02-04 2010-06-02 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
WO2003070285A1 (en) 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0410995D0 (en) 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) * 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
LT3193835T (lt) 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DE69232462T2 (de) * 1991-12-18 2002-10-10 Astrazeneca Ab Formoterol und budesonide enthaltende zusammensetzung
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments

Also Published As

Publication number Publication date
CZ342396A3 (en) 1997-07-16
KR970703132A (ko) 1997-07-03
NZ287425A (en) 1998-05-27
DE69523587T2 (de) 2002-06-27
IL113794A (en) 2000-10-31
PT760649E (pt) 2002-04-29
CY2294B1 (en) 2003-07-04
DK0760649T3 (da) 2002-01-28
PL317225A1 (en) 1997-03-17
CZ285966B6 (cs) 1999-12-15
GB9410222D0 (en) 1994-07-06
HK1004192A1 (en) 1998-11-20
NO313785B1 (no) 2002-12-02
HU9603227D0 (en) 1997-01-28
DE69523587D1 (de) 2001-12-06
SI0760649T1 (en) 2002-04-30
TW438604B (en) 2001-06-07
NO964938L (no) 1996-11-20
FI964634A (sv) 1996-11-20
ES2164767T3 (es) 2002-03-01
HU223316B1 (hu) 2004-05-28
KR970703130A (ko) 1997-07-03
FI118512B (sv) 2007-12-14
IL113794A0 (en) 1995-08-31
RU2161485C2 (ru) 2001-01-10
AU2614595A (en) 1995-12-18
AU710821B2 (en) 1999-09-30
MX9605650A (es) 1998-05-31
CN1098680C (zh) 2003-01-15
NO964938D0 (no) 1996-11-20
EP0760649A1 (en) 1997-03-12
ZA954101B (en) 1996-01-29
US5993781A (en) 1999-11-30
CN1148804A (zh) 1997-04-30
KR100361413B1 (ko) 2003-02-19
WO1995031964A1 (en) 1995-11-30
ATE207734T1 (de) 2001-11-15
EP0760649B1 (en) 2001-10-31
JPH10500420A (ja) 1998-01-13
HUT76552A (en) 1997-09-29
BR9507746A (pt) 1997-08-19
PL180318B1 (pl) 2001-01-31
CA2190763A1 (en) 1995-11-30

Similar Documents

Publication Publication Date Title
DE69523587D1 (de) Fluticasonpropionat-formulierungen
AU4346996A (en) Pharmaceutical aerosol containing at least one sugar
CA2125665A1 (en) Medicaments
MY118856A (en) Dry heat sterilization of a glucocorticosteroid
PT918507E (pt) Formulacoes em aerossol
GEP20002140B (en) Pharmaceutical Aerosol Composition
HU9603200D0 (en) Use of gel formulations as dressing agents
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
SE9402880D0 (sv) New peptide derivatives
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
NO964688D0 (no) Ny peptid-aktivsubstans og fremstilling av denne
BR9507848A (pt) Composição farmcéutica contendo espiramicina eventualmente em associação com o metronizadol
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118512

Country of ref document: FI

MA Patent expired